Business Context and Reporting Period
This Form 8-K was filed by ChromaDex Corporation on July 12, 2011. The report details a material definitive agreement entered into on the same date by ChromaDex, Inc., a wholly owned subsidiary of the registrant.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. It focuses exclusively on the terms of a new licensing agreement.
- License Fees: Annual maintenance fees ranging from $15,000 to $75,000 prior to commercial sales.
- Royalties: Earned royalties on net sales of licensed products.
- Milestone Payments: Payments due upon completion of strategic milestones.
- Upfront Consideration: A cash payment to Cornell University (amount not disclosed).
Material Changes
The primary material change is the execution of a License Agreement with Cornell University. This agreement grants ChromaDex a worldwide, exclusive, sublicensable right to use patent rights related to the compound Nicotinamide Riboside for use in dietary supplements, food, food additives, cosmetics, and drug products.
Outlook, Risks, and Contingencies
Management Obligations: ChromaDex has agreed to diligently develop, manufacture, and sell licensed products and must achieve specific milestone events.
Termination Risks:
- Cornell may terminate the agreement early if ChromaDex fails to satisfy certain milestone requirements.
- ChromaDex may terminate the agreement at any time with 90 days' prior written notice.
Confidentiality: Certain terms of the agreement are subject to confidential treatment and will be detailed in the subsequent Form 10-Q for the quarter ended October 1, 2011.
Investor Verification Checklist
- Verify the exact amount of the upfront cash payment to Cornell University, which is not disclosed in this filing.
- Review the specific strategic milestones required to prevent early termination by Cornell.
- Examine the detailed royalty rates and sublicensing terms in the upcoming Form 10-Q.
- Confirm the expiration dates of the underlying patent rights to determine the agreement's maximum duration.